A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium

Authors

Xiaobao Yao
D. Ye
Yuchen Ye (ORCID: https://orcid.org/0009-0001-4270-6373)
Yujue He (ORCID: https://orcid.org/0009-0005-7102-4637)
Can Liu (ORCID: https://orcid.org/0009-0003-8259-5174)
Yanping Lan (ORCID: https://orcid.org/0000-0003-0308-0280)
Zhen Xun (ORCID: https://orcid.org/0000-0002-4242-3402)
Shanjian Chen
Siyi Xu (ORCID: https://orcid.org/0000-0002-5147-2644)
Caorui Lin (ORCID: https://orcid.org/0000-0002-8680-3159)
Renquan Jiang
Bin Yang (ORCID: https://orcid.org/0000-0002-3944-8035)
Qishui Ou (ORCID: https://orcid.org/0000-0002-9923-3212)
Ke Ma (ORCID: https://orcid.org/0000-0002-4577-9818)
Xin Yang (ORCID: https://orcid.org/0000-0001-9452-3256)
Yanfang Zhang (ORCID: https://orcid.org/0000-0001-7614-0067)
Wennan Wu
Xinyao Yang (ORCID: https://orcid.org/0000-0002-1349-9141)
Jing Chen
Qi Zheng (ORCID: https://orcid.org/0000-0002-0506-9133)

Institutions

Fujian Medical University (CN)
Second Hospital of Shandong University (CN)
First Affiliated Hospital of Fujian Medical University (CN)

Publication Details

Journal: JHEP Reports
Published: 2025-05-23
DOI: https://doi.org/10.1016/j.jhepr.2025.101456
Citations: 2
Primary Topic: Liver Disease Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 2.71

Funders

National Natural Science Foundation of China
Fujian Medical University

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium

Xiaobao Yao, D. Ye, Yuchen Ye, Yujue He et al.

May 23, 2025

2 citations

JHEP Reports

Liver Disease Diagnosis and Treatment

2.71

article

A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium

Xiaobao Yao, D. Ye, Yuchen Ye, Yujue He, Can Liu, Yanping Lan, Zhen Xun, Shanjian Chen, Siyi Xu, Caorui Lin, Renquan Jiang, Bin Yang, Qishui Ou, Ke Ma, Xin Yang, Yanfang Zhang, Wennan Wu, Xinyao Yang, Jing Chen, Qi Zheng

May 23, 2025article en

2 citations

Abstract

No abstract available for this paper.

JHEP ReportsVol. 7(8)

Fujian Medical University (CN), Second Hospital of Shandong University (CN), First Affiliated Hospital of Fujian Medical University (CN)

National Natural Science Foundation of China, Fujian Medical University

Good health and well-being

Openalex Percentile: Top 10%

Liver Disease Diagnosis and Treatment

2.71

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium — Xiaobao Yao, D. Ye, et al. · JHEP Reports (2025) | TGRS Research Map | TGRS